ClinicalTrials.gg
RecruitingNCT07254364Updated Oct 5, 2026

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

An interventional study of Standardized meal 1 in Insulin Response and Type 1 Diabetes, sponsored by Texas A&M University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Texas A&M University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 5, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.

Read the detailed description

The goal of the proposed research is to develop a wearable device that can directly stimulate sweat secretion and rapidly quantify the concentration of insulin in sweat. In stark contrast to a blood draw and subsequent insulin quantification in a clinical lab, the envisioned wearable sweat sensor can noninvasively and rapidly quantify insulin at any desired time at home. This study will validate the performance of the wearable devices for in situ quantification of insulin in sweat and determine the concentration correlation between sweat, dermal interstitial fluid, and blood.

The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A\&M University located in the Human Clinical Research Building) affiliated with Texas A\&M University. Some study procedures (e.g., body composition) may be skipped if completed within the past 3 months at CTRAL. All data will be recorded in Case Report Form and stored in the Research Electronic Data Capturing (REDCap) System.

Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, The Six-Minute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit. Questionnaires about overall health and well-being will also be completed. The study visit will begin with vital signs. Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites. The research nurse will place a catheter (small, flexible, plastic tube) in a vein of the arm or hand. The hand will be placed in a warmed box to increase blood flow. There will be a device with electrodes used to generate and collect sweat on the forearm. Once sweat collection is started, we will also apply a microneedle patch to the forearm of the subject for 5-30 minutes duration. Microneedle patches (sensors) are small flexible sticker-like devices. They will be applied to the skin using a small spring loaded applicator to measure the chemical analytes in the dermal interstitial fluids. After 2 hours of baseline biological samples of sweat, dermal interstitial fluid, and blood have been collected, the researchers will provide a standardized meal as a liquid drink consisting of whey, maltodextrin and sunflower oil, flavored using vanilla sugar-free instant pudding. Biological sampling will continue to occur for the following 5 hours.

02

Conditions studied

  • Insulin Response
  • Type 1 Diabetes
03

In context

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 32 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Texas A&M University is the lead sponsor of 123 studies on the registry; 23 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age
  • ● 18-30 years old
  • ● 50-90 years old
  • between 18 and 35 kg/m2
  • Ability to walk, sit down, and stand up (independently or with a walking assistance device)
  • Willingness to lay supine in bed for up to 9 hours
  • Willingness and ability to comply with the protocol

Exclusion criteria

Exclusion criteria

  • Known allergy to any of the components of the meal or agents used for the application of the devices

    • Sunflower oil
    • Maltodextrin
    • Whey protein
    • Pilocarpine solutions
  • Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active , heart failure, kidney disease, liver disease, /AIDS, asthma (moderate to severe), Hep (A, B, or C)
  • History of untreated metabolic disease including hepatic or renal disorder
  • Presence of acute illness or metabolically unstable chronic illness
  • Active dependence on alcohol or drugs
  • Use of a short course of oral within 4 weeks preceding study day
  • Current use of long-term oral corticosteroids
  • Presence of fever within the last 3 days
  • Planned elective surgery requiring 2 or more days of hospitalization during the entire study
  • (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)
  • Failure to give or Investigator's uncertainty about the willingness or ability of the subject
  • Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Standardized liquid meal drink

    The researchers will provide a standardized drink consisting of whey, maltodextrin and sunflower oil, flavored using vanilla sugar-free instant pudding.

    Other: Standardized meal 1

Interventions

  • OtherStandardized meal 1

    Meal contains Whey powder (60g) as protein, Maltodextrin (Polycose; 170g) as carbohydrate, and Sunflower Oil (48g) as the fat source. The meal is mixed and flavored using vanilla sugar-free instant pudding.

06

What researchers measure

Primary outcomes

  1. Quantification of protein biomarkers

    Time-varying plasma insulin concentrations and correlation between sweat and dermal interstitial fluid.

    Time frame: up to 9 hours, 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Enrollment
92→32
Oct 5, 2026
Eligibility
1 inclusion criterion edited, 2 added, 4 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedAge
  • EditedAge● 18-9030 years old
  • RemovedType 1 Diabetes (T1D) group only
  • Removed● Recently diagnosed (≤ 5 years)
  • Removed● Established diagnosis (> 5 years)
  • Added● 50-90 years old
  • RemovedWillingness and ability to comply with the protocol including wearing of a continuous glucose monitor
Exclusion criteria
  • EditedEstablished diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)
Oct 5, 2026
Interventions
Removed Standardized meal 2·Standardized meal 3·Standardized meal 4·Standardized meal 5·Standardized meal 6
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Enrollment 92→32
    Eligibility 1 inclusion criterion edited, 2 added, 4 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedAge
    • EditedAge● 18-9030 years old
    • RemovedType 1 Diabetes (T1D) group only
    • Removed● Recently diagnosed (≤ 5 years)
    • Removed● Established diagnosis (> 5 years)
    • Added● 50-90 years old
    • RemovedWillingness and ability to comply with the protocol including wearing of a continuous glucose monitor
    Exclusion criteria
    • EditedEstablished diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)
    Interventions Removed Standardized meal 2·Standardized meal 3·Standardized meal 4·Standardized meal 5·Standardized meal 6
    + 3 other changes: verification date, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07254364
Responsible party
Marielle PKJ Engelen, PhD (Professor, Texas A&M University) — Principal investigator
First posted
Nov 28, 2025
Start date
Sep 11, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 5, 2026

Study contacts

Nicolaas Deutz
Contact
nep.deutz@ctral.org
979-458-1484
Laura Ruebush
Contact
le.ruebush@ctral.org
979-458-1484

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion